Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Peter Webb

Dermatology San Mateo, CA Medical Doctor

NPI 1023030582 CMS profile 449290

136 N San Mateo Dr Fl 2, San Mateo, CA 94401

Open in the dashboard

General payments

$3,813

158 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Peter Webb of San Mateo, CA is reported in the CMS Open Payments database as having received $3,813 across 158 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,039 58
2021 General $1,139 50
2020 General $102 6
2019 General $1,533 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Webb
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Peter Webb were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Peter Webb Dermatology median Middle half National median
2019 $1,533 $454 $129–$1,240 $163
2020 $102 $235 $81–$756 $114
2021 $1,139 $377 $108–$1,108 $132
2022 $1,039 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AngioDynamics, Inc. $660 1 payment
  2. AbbVie, Inc. $586 22 payments
  3. Janssen Biotech, Inc. $349 17 payments
  4. Pfizer Inc. $342 19 payments
  5. LEO Pharma Inc. $321 26 payments
  6. Novartis Pharmaceuticals Corporation $270 14 payments
  7. Regeneron Healthcare Solutions, Inc. $229 11 payments
  8. UCB, Inc. $196 8 payments
  9. Genzyme Corporation $181 8 payments
  10. Sun Pharmaceutical Industries Inc. $173 8 payments
  11. Other $508 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,153 157 payments
  2. Education $660 1 payment
Products named General payments · program years 2019–2022
  1. EVLT $660 1 payment
  2. HUMIRA $355 12 payments
  3. EUCRISA $342 19 payments
  4. SIMPONI ARIA $289 14 payments
  5. STELARA $289 14 payments
  6. REMICADE $289 14 payments
  7. SIMPONI $289 14 payments
  8. ADBRY $273 24 payments
  9. SKYRIZI $230 10 payments
  10. DUPIXENT $229 11 payments
  11. Other $1,638 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record